Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Retained Earnings (2016 - 2025)

Vanda Pharmaceuticals' Retained Earnings history spans 16 years, with the latest figure at -$394.8 million for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 533567.57% to -$394.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$394.8 million, a 533567.57% decrease, with the full-year FY2025 number at -$394.8 million, down 533567.57% from a year prior.
  • Retained Earnings hit -$394.8 million in Q4 2025 for Vanda Pharmaceuticals, down from -$253.6 million in the prior quarter.
  • Over the last five years, Retained Earnings for VNDA hit a ceiling of $103000.0 in Q2 2021 and a floor of -$394.8 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$145.2 million across 5 years, with a median of -$164.1 million in 2021.
  • Biggest five-year swings in Retained Earnings: soared 100.05% in 2021 and later crashed 533567.57% in 2025.
  • Tracing VNDA's Retained Earnings over 5 years: stood at -$164.2 million in 2021, then skyrocketed by 99.27% to -$1.2 million in 2022, then plummeted by 12925.31% to -$155.4 million in 2023, then surged by 100.05% to $74000.0 in 2024, then crashed by 533567.57% to -$394.8 million in 2025.
  • Business Quant data shows Retained Earnings for VNDA at -$394.8 million in Q4 2025, -$253.6 million in Q3 2025, and -$231.0 million in Q2 2025.